The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children
Abstract
BACKGROUND: The measles-mumps-rubella vaccine has been associated with immune thrombocytopenia purpura in 2 small studies. METHODS: By using the Vaccine Safety Datalink, we identified measles-mumps-rubella-vaccinated children aged 1 to 18. A case of immune thrombocytopenia purpura was defined as a patient with a platelet count of < or = 50,000/microL with clinical bleeding and normal red and white blood cell indices. The immune thrombocytopenia purpura incidence rates during exposed (42 days after vaccination) and unexposed time periods were determined. A retrospective cohort of vaccinated children was used to determine incident rate ratios for children aged 1 to 18 years, 12 to 23 months, and 12 to 15 months. RESULTS: A total of 1,036,689 children received 1,107,814 measles-mumps-rubella vaccinations; there were 259 confirmed patients with immune thrombocytopenia purpura. Because only 5 exposed cases occurred after age 2, analyses were limited to children aged 12 to 23 months. Exposed patients aged 12 to 23 months had lower median platelet counts than those who were unexposed and had similar median duration of illness (11 vs 10 days). The incident rate ratio was highest for children aged 12 to 15 months at 7.10. The incident rate ratio for boys aged 12 to 15 months was 14.59, and the incident rate ratio for girls in the same age group was 3.22. Seventy-six percent of immune thrombocytopenia purpura cases in children aged 12 to 23 months were attributable to measles-mumps-rubella vaccination. This vaccine causes 1 case of immune thrombocytopenia purpura per every 40,000 doses. CONCLUSION: Measles-mumps-rubella vaccine that is given in the second year of life is associated with an increased risk of immune thrombocytopenia purpura.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Twenty cases had been classified as exposed and 43 as not exposed.”
From Vaccines for measles, mumps and rubella in children (2012) · cites this paper as France 2008
Citations
Cites
Rates of pediatric injuries by 3-month intervals for children 0 to 3 years of age
Agran, P. F., Anderson, C., Winn, D., Trent, R., Walton-Haynes, L., & Thayer, S. (2003) · Pediatrics · doi:10.1542/peds.111.6.e683 · Cited by 398
Relative Incidence Estimation from Case Series for Vaccine Safety Evaluation
Farrington, P. (1995) · Biometrics · doi:10.2307/2533328 · Cited by 363
Chen, R. T., Glasser, J. W., Rhodes, P., Davis, R. L., Barlow, W. E., Thompson, R. S., Mullooly, J. P., BLACK, S. B., Shinefield, H. R., Vadheim, C. M., et al. (1997) · PEDIATRICS · doi:10.1542/peds.99.6.765 · Cited by 346
Kühne, T., Buchanan, G. R., Zimmerman, S. A., Michaels, L. A., Kohan, R., Berchtold, W., & Imbach, P. A. (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00535-3 · Cited by 284
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study
Kühne, T., Imbach, P. A., Bolton‐Maggs, P. H. B., Berchtold, W., Blanchette, V. S., & Buchanan, G. R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07219-1 · Cited by 246
Case Series Analysis of Adverse Reactions to Vaccines: A Comparative Evaluation
Farrington, P., Nash, J., & Miller, E. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008695 · Cited by 233
Short report: Idiopathic thrombocytopenic purpura and MMR vaccine
Miller, E. J. (2001) · Archives of Disease in Childhood · doi:10.1136/adc.84.3.227 · Cited by 228
Adverse Events Associated with Childhood Vaccines
Institute of Medicine (1994) · National Academies Press eBooks · doi:10.17226/2138 · Cited by 214
Impact of Vaccines Universally Recommended for Children—United States, 1900-1998
(1999) · JAMA · doi:10.1001/jama.281.16.1482-jwr0428-2-1 · Cited by 165
MMR vaccine and idiopathic thrombocytopaenic purpura
Black, C., Kaye, J. A., & Jick, H. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01790.x · Cited by 137 · cited 3×
“Total ITP cases, N 63 69 56 60 Gender, n (%) Male 33 (52) 31 (45) 30 (54) 29 (48) Female 30 (48) 38 (55) 26 (46) 31 (52) Platelet count at diagnosis (25th, 75th percentiles), per L 7000 (3000, 18 000) 8500 (3000, 18 500) 8000 (3000, 17 000) 7000 (4000, 16 000) Referral to hematologist, n (%) 52 (83) 51 (74) 48 (86) 48…”
Flagged first, then by citations
Research works printed but not linked: 1
- Chen RT. Safety of vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: WB Saunders Company;1999:1144–1163
Cited by
Sorted by citations
Items 101–163 of 163
Aldali, J. A., Alotaibi, B. A., Aldali, H. J., Alasiri, G. A., Alaseem, A. M., Almuqrin, A., Alshalani, A., & Alotaibi, F. T. (2023) · Biomedicines · doi:10.3390/biomedicines11082203 · Cited by 6
“Similar events were previously recorded in children after receiving the measles, mumps, and rubella (MMR) vaccine [36].”
BackgroundResultHo, W., Lu, M., Hu, F., Lee, C.-C., Huang, L., Jou, S., Lin, D., & Lin, K. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2011.06.025 · Cited by 6
Physicians' confidence in vaccine safety studies
O’Leary, S. T., Allison, M. A., Stokley, S. K., Crane, L. A., Hurley, L. P., Beaty, B. L., & Kempe, A. (2013) · Preventive Medicine · doi:10.1016/j.ypmed.2013.01.001 · Cited by 6
“Though adverse events are rare, post-licensure studies have successfully identified potential vaccine-associated events (Klein et al., 2010; France et al., 2008; O’Leary et al., 2012), the most notable of which was the withdrawal of the rhesus-based rotavirus vaccine (RotaShield, Wyeth-Lederle) 11…”
BackgroundSharma, K., Patel, S., Patel, Z., Patel, K. B., Shah, D. B., Doshi, J. S., Chokshi, P., Sharma, C., Amdani, M. M., Parabtani, A., et al. (2022) · Cureus · doi:10.7759/cureus.26480 · Cited by 6
“According to one study, approximately one instance of ITP occurs in approximately 40,000 children who receive the MMR vaccine [34].”
BackgroundOwatanapanich, S., Wanlapakorn, N., Tangsiri, R., & Poovorawan, Y. (2014) · PubMed · Cited by 6
Pharmacoepidemiologic Studies of Vaccine Safety
Chen, R. T., Glanz, J. M., & Vellozzi, C. J. (2012) · Pharmacoepidemiology · doi:10.1002/9781119959946.ch26 · Cited by 6
Diab, A. M., Abouamer, A. A., Motaleb, G. S. A., Eid, K. A., & Abdelnaiem, H. I. (2021) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2021-20-3-26-30 · Cited by 5
Xu, S., Sy, L. S., Han, B., Hong, V. X., Bruxvoort, K. J., Lewin, B. J., Holmquist, K. J., & Qian, L. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae141 · Cited by 5
BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura
Ghosh, A. K., Bhushan, S. R., Lopez, L. D. R., Sampat, D., Salah, Z., & Hatoum, C. A. (2022) · Case Reports in Medicine · doi:10.1155/2022/5603919 · Cited by 5
Qian, L., Tseng, H. F., Sy, L. S., & Jacobsen, S. J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.064 · Cited by 5
Levi, M., Donzellini, M., Varone, O., Sala, A., Bechini, A., Boccalini, S., & Bonanni, P. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2014.55.4.455 · Cited by 5
Monitoring Vaccine Safety: United States Vaccine Safety Surveillance Systems
Zauche, L. H., Miller, E. R., Kim, S. S., Jazwa, A., & Shay, D. K. (2025) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2025.07.016 · Cited by 4
“RCA has helped VSD confirm rare AEs after vaccination, including febrile seizures following the measles, mumps, and rubella (MMR) vaccine (France et al., 2008; Klein et al., 2010) and Guillain−Barre syndrome following the Janssen COVID-19 vaccine (Hanson et al., 2022; Klein et al., 2021).”
Sato, S., Katsuta, T., Kawazoe, Y., Takahashi, M., Murata, F., Maeda, M., Fukuda, H., & Kamidani, S. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.11.053 · Cited by 4
Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines
Qasim, H., Rahhal, A. A. A., Husain, A., Alammora, A., Alsa’ed, K., Alsayed, A., Faiyoumi, B. A., AbuAfifeh, L. M., Abu‐Tineh, M., Alshurafa, A., et al. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s396026 · Cited by 4
Púrpura fulminante posvaricelosa: potencialmente mortal
Blanco, A. H., Montero, R. G., Moreno, M. M. U., Martínez-Moratalla, J. C., & Benavent, M. M. (2009) · Anales de Pediatría · doi:10.1016/j.anpedi.2008.11.018 · Cited by 4
SARS‐CoV‐2 vaccination in pediatric patients with immune thrombocytopenia
Hillier, K., Rothman, J., Klaassen, R. J., Neunert, C. E., Rose, M. J., Grace, R. F., & Lambert, M. P. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29760 · Cited by 4
Safety of Immunization for Children with Immune Thrombocytopenia
Wang, X., Feng, T., Wang, C., Li, J., Ge, Y., Zhai, X., Wang, H., & Zeng, M. (2024) · Vaccines · doi:10.3390/vaccines12010066 · Cited by 4
“Only the first dose of the measles–mumps–rubella vaccine has been demonstrated to have a clear causal relationship with the occurrence of ITP with some biological plausibility, given that the measles virus itself can cause ITP [7].”
BackgroundPérez-Vilar, S., Gutiérrez-Gimeno, M. V., Rodríguez-Galán, M. A., Díez‐Domingo, J., Puig‐Barberà, J., Gomar-Fayos, J., & Alguacil-Ramos, A. M. (2012) · Anales de Pediatría · doi:10.1016/j.anpedi.2012.07.013 · Cited by 4
Worsening of immune thrombocytopenic purpura in SARS-CoV-2 vaccinated patients
Ramírez, P. G., García, L. C., & Cilleruelo, J. M. A. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.09.017 · Cited by 4
Pharmacoepidemiologic Studies of Vaccine Safety
Chen, R. T., Glanz, J. M., & Shimabukuro, T. T. (2019) · Pharmacoepidemiology · doi:10.1002/9781119413431.ch20 · Cited by 4
Xu, S., Sy, L. S., Huang, X., Hong, V. X., Han, B., Bruxvoort, K. J., Lewin, B. J., Holmquist, K. J., & Qian, L. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf115 · Cited by 3
Vaccination Associated Acute Immune Thrombocytopenic Purpurai Children
Karaman, S. A. K. (2014) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000260 · Cited by 3
Kitazawa, J., Nakadate, H., Matsubara, K., Takahashi, Y., Ishiguro, A., Inoue, E., Sasahara, Y., Fujisawa, K., Maeda, N., Oka, T., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03230-7 · Cited by 3
Acute immune thrombocytopenic purpura following oral polio vaccination
Akbayram, S., Karaman, K., Ece, İ., & Akbayram, H. T. (2014) · Platelets · doi:10.3109/09537104.2014.980798 · Cited by 3
“In the literature, there is only one reported case of a child with ITP after oral polio vaccine [4].”
BackgroundLababidi, S., Sutherland, A., Krasnicka, B., Forshee, R. A., & Anderson, S. A. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.67 · Cited by 3
Gruson, B., & Bussel, J. B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00047-2 · Cited by 3
Karaman, K., & Doğan, E. (2023) · Eastern Journal Of Medicine · doi:10.5505/ejm.2023.26675 · Cited by 2
Salveridou, K., Tzamalis, T., Klaiber-Hakimi, M., Haase, S. P., Gröpper, S., & Giagounidis, A. A. N. (2024) · Hematology Reports · doi:10.3390/hematolrep16040057 · Cited by 2
Algaissi, A. A., Alamer, E., Jeraiby, M., Alomaish, A. R., Elrhima, O. A., Qumayi, S., Qasir, N. A., Areeshi, H., Masmali, A., & Alhazmi, A. (2022) · Saudi Medical Journal · doi:10.15537/smj.2022.43.6.20220135 · Cited by 2
Impact of SARS-CoV-2 AstraZeneca Vaccine on Safety and Blood Elements of Egyptian Healthcare Workers
Meshref, T. S., Hamad, D. A., Aly, M. M., Kamal, D. T., Elkhayat, M., & Elghazally, S. A. (2023) · Indian Journal of Occupational and Environmental Medicine · doi:10.4103/ijoem.ijoem_275_22 · Cited by 2
“[6] This study aimed to identify adverse events following vaccination with the COVID‑19 AZ vaccine on Egyptian HCWs.”
Risk of Immune Thrombocytopenic Purpura Recurrence Following Second Measles-Containing Vaccine Dose
Zerbo, O., Modaressi, S., FIREMAN, B. H., Ross, P., Goddard, K., Nelson, J. C., Glanz, J. M., Irving, S. A., Lewin, B. J., DeSilva, M. B., et al. (2025) · PEDIATRICS · doi:10.1542/peds.2025-070931 · Cited by 2
Teo, S. P. (2021) · PubMed Central · doi:10.11909/j.issn.1671-5411.2021.11.006 · Cited by 2
“For example, a multinational network cohort study using thirteen databases from eight countries reported population-based, age and gender specific background incidence rates, and found that some AESI such as myocardial infarction and Guillain-Barre syndrome increased with age, while anaphylaxis and appendicitis were m…”
BackgroundThe vaccine adverse event reporting system and vaccine safety research in the genomics era
Davis, R. L. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.12.018 · Cited by 2
Vadasz, Z., & Toubi, E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-63269-2.00056-8 · Cited by 2
[Worsening of immune thrombocytopenic purpura in SARS-CoV-2 vaccinated patients].
Ramírez, P. G., García, L. C., & Cilleruelo, J. M. A. (2022) · PubMed Central · doi:10.1016/j.medcli.2021.09.010 · Cited by 2
Johnson, M., Windsor, R., Schmidt, J. L., Raczek, D. J., & Moore, G. E. (2025) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.70013 · Cited by 1
Can Vaccines Cause Chronic Diseases?
Nyquist, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7438-8_18 · Cited by 1
Novicevic, S., Igrutinovic, Z. R., & Medović, R. (2014) · Medicinski casopis · doi:10.5937/mckg48-3381 · Cited by 1
Ivanko, I., Ćelap, I., Margetić, S., Marijančević, D., Josipović, J., & Gaćina, P. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.008 · Cited by 1
Systems Biology: A New Era for Vaccine Development; from Deductive Toward Inductive
Debnath, U., & Ghosh, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-9462-5_13 · Cited by 1
Measles, Mumps, and Rubella Vaccine: A Triad to Autoimmunity
Perricone, C., Valesini, G., & Shoenfeld, Y. (2015) · doi:10.1002/9781118663721.ch13 · Cited by 1
Iskander, J., Vellozzi, C. J., Gidudu, J., & Chen, R. T. (2012) · doi:10.1002/9781118345313.ch33 · Cited by 1
Immune Thrombocytopenic Purpura: Between Infections and Vaccinations
Perricone, C., Rinaldi, M., Perricone, R., & Shoenfeld, Y. (2015) · doi:10.1002/9781118663721.ch28
Known Vaccine-Associated Adverse Events
Pahud, B. A., & Harrison, C. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7438-8_3
Measles with overt jaundice in an adult aged over 60 years
Seishima, M., Shibuya, Y., & Kato, G. (2009) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2008.03126.x
Dittmann, S. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00032-5
Athiany, H., Wanjoya, A., Orwa, G. O., & Mwalili, S. M. (2020) · International Journal of Data Science and Analysis · doi:10.11648/j.ijdsa.20200606.12
“The vaccine has also been associated with increased incidence of ITP [28], although this is said to resolve after a period of seven days [28] or six months for acute conditions.”
BackgroundCabrera, E., Amaya, A. M. T., Vallejo-Ortega, M., Ballesteros, A. L., Sarmiento-Urbina, I. C., Acosta, A. D. C., Castro-Dager, Á., Montenegro-Aguilar, L. P., & Lotero, V. (2021) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v69n3.82381
Basi genetiche della risposta immune alle vaccinazioni.
Cardinale, F., Atti, M. D., Bartolozzi, G., Martire, B., Moschese, & Rizzo, C. (2012) · Cineca Institutional Research Information System (Tor Vergata University)
van Weert, H. C. P. M. (2021) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2739-3_4
van Weert, H. C. P. M. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-1696-0_4
Clinical Presentations of Idiopathic Thrombocytopenic Purpura
Rahema, M. I., & Mohammed, M. I. (2022) · IAR Journal of Medical Sciences · doi:10.47310/iarjms.2022.v03i04.004
Reef, S. E., & Plotkin, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00054-2
Xu, S., Narwaney, K. J., Nguyen, A. P., Binswanger, I. A., McClure, D. L., & Glanz, J. M. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5708
“28,29 30 – 32 However, the number of window types is usually small in risk interval and SCCS analyses, mostly just two: risk window and control window.”
BackgroundPost-Mumps vaccination parotitis
Alemayehu, T. (2024) · Ethiopian Journal of Pediatrics and Child Health · doi:10.4314/ejpch.v18i2.7
Cherry, J. D., & Baker, A. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00174-6
Lim, E., Jeong, N., Won, H., & Choi, N. (2025) · Journal of Health Informatics and Statistics · doi:10.21032/jhis.2025.50.2.113
Severe Immune Thrombocytopenia and Myositis After 23-Valent Pneumococcal Vaccine
Gampala, A. R., Minnaganti, D., & Weidemann, D. K. (2025) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2025.07.003
Halma, M. T. J., Dhillon, S., Gracidas-Carrion, C. A., Hassaan, S., Bellavite, P., Fede, G. D., & Varón, J. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1014628 · Cited by 1
Neale, V., Broughton, S., Hall, H. R., Caldecott, N., Paul, A., Skelly, B. J., Glanemann, B., & Swann, J. W. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag057
Real and Perceived Risks from Live Viral Vaccines
Giuliani, A. A. M., & Pannaraj, P. S. (2026) · Springer eBooks · doi:10.1007/978-1-0716-5464-4_21
Dudley, M. Z., Ali, H., Villaescusa, M. R., & Law, B. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129120
Metadata
- Authors
- France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., Marcy, M., Mullooly, J. P., Jackson, L. A., Nordin, J., Belongia, E. A., Hohman, K., Chen, R. T., Davis, R., & for the Vaccine Safety Datalink Team
- Affiliations
- Department of Preventive Medicine
- Kaiser Permanente (US)
- Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California
- Group Health Cooperative (US)
- Regions Hospital (US)
- Marshfield Clinic Research Foundation (US)
- Harvard Pilgrim Health Care (US)
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- PEDIATRICS
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2008-03-01
- Volume
- 121
- Issue
- 3
- Pages
- e687-e692
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2007741934
- Cited by
- 165
- References
- 17
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 9 · 2016: 6 · 2015: 11 · 2014: 8 · 2013: 14 · 2012: 12
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- idiopathic thrombocytopenic purpura, MMR vaccine, vaccine adverse events, children, platelet count, incidence rate ratio, attributable risk, infants, sex differences
- MeSH terms
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Immunization Schedule, Male, Purpura, Thrombocytopenic, Registries, Retrospective Studies, Severity of Illness Index, United States, Cohort Studies, Incidence, Poisson Distribution, Age Distribution, Sex Distribution, Risk Assessment, Measles-Mumps-Rubella Vaccine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
